Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product ...

Pacific Biosciences of California is back in focus as analysts adjust their price targets by increments of $0.50, reflecting ...

PacBio and Intus Bio have launched GutID, the first commercial human gut health test, showcasing their collaboration and innovation in microbiome research. GutID utilizes PacBio's HiFi sequencing ...

Pacific Biosciences of California (PACB) ended the recent trading session at $1.66, demonstrating a -1.19% change from the preceding day's closing price. The stock's change was less than the S&P 500's ...

MENLO PARK, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into the ...

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the addition of two tertiary analysis partners to PacBio Compatible. Geneyx and Golden ...

Pacific Biosciences of California (PACB) shares fell 16% after the company reported Q1 results that included a wider-than-expected revenue miss and weaker profitability metrics. PacBio reported Q1 non ...

Ships a record number of PacBio sequencers in 2023, including 173 Revio™ systems, and announces record fourth quarter preliminary consumable revenue of $18.9 million as demand for long-read sequencing ...

Pacific Biosciences of California, Inc. (NASDAQ:PACB) has gained more than 12% over the past month and roughly 35% since the ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product development. The optimism, led by decent 2024 preliminary results and restructuring ...